Parry Pharma Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
as on 03-01-2025
- Paid Up Capital ₹ 0.50 M
as on 03-01-2025
- Company Age 32 Year, 2 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 1.57 Cr
as on 03-01-2025
- Revenue -13.94%
(FY 2021)
- Profit -27.44%
(FY 2021)
- Ebitda -20.23%
(FY 2021)
- Net Worth 4.70%
(FY 2021)
- Total Assets -3.07%
(FY 2021)
About Parry Pharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.50 M.
The company currently has active open charges totaling ₹1.57 Cr.
Nupur Bhagat, Neha Sheth, and Nitin Bhagat serve as directors at the Company.
- CIN/LLPIN
U24231GJ1992PTC018540
- Company No.
018540
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
06 Nov 1992
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Company Details
- Location
Ahmedabad, Gujarat, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Parry Pharma Private Limited offer?
Parry Pharma Private Limited offers a wide range of products and services, including Personal Care, Oral Care, Skin Care, Facewash, Bath Essentials, Acne Care.
Who are the key members and board of directors at Parry Pharma?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Nupur Bhagat | Director | 05-Aug-2024 | Current |
| Neha Sheth | Director | 05-Aug-2024 | Current |
Nitin Bhagat  | Director | 06-Nov-1992 | Current |
Financial Performance of Parry Pharma.
Parry Pharma Private Limited, for the financial year ended 2021, experienced significant reduction in revenue, with a 13.94% decrease. The company also saw a substantial fall in profitability, with a 27.44% decrease in profit. The company's net worth moved up by a moderate rise of 4.7%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Parry Pharma?
Unlock access to Parry Pharma's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Hdfc Bank Limited Creation Date: 08 Oct 2024 | ₹0.70 M | Open |
Others Creation Date: 24 Sep 2024 | ₹1.50 Cr | Open |
How Many Employees Work at Parry Pharma?
Parry Pharma has a workforce of 5 employees as of Apr 06, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Parry Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Parry Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
